ReNeuron Group PLC - developer of cell-based therapeutics - Says human retinal progenitor cell therapeutic candidate is currently undergoing phase 2a clinical evaluation for the treatment of the inherited blindness-causing disorder retinitis pigmentosa.
"The study uses a cryopreserved hRPC formulation, enrols subjects with advanced RP with some remaining central vision and, thus far, has been conducted at two clinical sites in the US," company explains.
It adds: "The company is pleased to report that dosing of the first cohort of three subjects in the phase 2a extension segment of the study is now complete. This segment of the study is treating up to nine subjects with RP at a higher dose level than the first ten subjects already treated in the study. In line with the clinical trial protocol, the data safety monitoring board for the study will review short term safety data from this first cohort during the next few weeks, before the study proceeds to dosing the next cohort."
Current stock price: 132.77 pence, up 16% on Friday
Year-to-date change: up 61%
By Paul McGowan; paulmcgowan@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Reneuron (RENE)